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Colorectal cancer (CRC) is the third most common malignancy 
in the world. Because CRC develops slowly from removable 
precancerous lesions, detection of the disease at an early stage 
during regular health examinations can reduce both the in-
cidence and mortality of the disease. Although sigmoidoscopy 
offers significant improvements in the detection rate of CRC, its 
diagnostic value is limited by its high costs and inconvenience. 
Therefore, there is a compelling need for the identification of 
noninvasive biomarkers that can enable earlier detection of 
CRC. Accordingly, many validation studies have been con-
ducted to evaluate genetic, epigenetic or protein markers that 
can be detected in the stool or in serum. Currently, the fe-
cal-occult blood test is the most widely used method of screen-
ing for CRC. However, advances in genomics and proteomics 
combined with developments in other relevant fields will lead 
to the discovery of novel non invasive biomarkers whose use-
fulness will be tested in larger validation studies. Here, non-
invasive molecular biomarkers that are currently used in clin-
ical settings and have the potential for use as CRC biomarkers 
are discussed. [BMB reports 2008; 41(10): 685-692]
Introduction
Colorectal cancer (CRC) is the third most common malignancy 
in the world. In addition, there are approximately 1,000,000 
new cases of CRC and 500,000 deaths associated with CRC 
each year. Indeed, CRC represents one of the primary causes 
of cancer deaths in Europe and the USA (1). In Korea, CRC is 
the fourth leading cause of mortality by cancer, and its in-
cidence is increasing (2). CRC is believed to develop slowly 
via a progressive accumulation of genetic mutations; therefore, 
the risk of recurrence and subsequent death due to CRC is 
closely related to the stage of the disease at the time of primary 
diagnosis. Recent studies have shown that shifting the de-
tection of the disease to an earlier stage via mass screening 
and intervening at this stage can reduce the risk of death from 
CRC (3, 4). These findings strongly demonstrate the clinical 
need for biomarkers for early detection of CRC.
    Biomarkers are substances that are used as indicators of a 
biological state. Accordingly, biomarkers have characteristics 
that enable them to be objectively measured and evaluated as 
indicators of normal biological processes, pathogenic proc-
esses, or pharmacologic responses to a therapeutic inter-
vention (5). One of the key requirements of a test for CRC is 
that it must allow detection of the disease at earlier stages so 
that the disease can be cured effectively. Accordingly, such 
tests should have high sensitivity and specificity while produc-
ing a low number of false-negative and false-positive results to 
prevent subjecting healthy individuals to unnecessary 
colonoscopies. Sigmoidoscopy offers significant improvements 
in detection rates for CRC. However, the diagnostic value of 
sigmoidoscopy is limited with regards to costs, risks, and in-
convenience (6, 7). Noninvasive biomarkers can be analyzed 
relatively easily and economically; therefore, they have the po-
tential to greatly enhance screening acceptance. Several non-
invasive tests for CRC detection are available, of which the fe-
cal-occult blooding test (FOBT) is the most commonly used 
(8-10). However, this method lacks sensitivity as well as specif-
icity for screening an average risk population. As a result, new 
cancer biomarkers that will further enhance the detection of 
the disease and trigger follow-up colonoscopies when neces-
sary must be developed. In addition to such screening bio-
markers, prognostic markers that predict the likely course of 
the cancer, stratification markers that predict the likely re-
sponse to a drug prior to beginning treatment, and efficacy 
markers that monitor the efficacy of drug treatment may even-
tually reduce the mortality rate of CRC.
    Recent advances in genomics and proteomics have con-
tributed to our understanding of pathways that control the 
growth, differentiation, and death of cells. Genomic techni-
ques such as DNA microarray analysis and proteomic methods 
such as 2-dimensional electrophoresis and mass spectrometry 
are now commonly used to evaluate the expression profiles of 
genes and proteins in cells, tissues, and bodily fluids (11, 12). 
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Analyte Subject Type Status
Fecal hemoglobin
K-ras
APC
L-DNA
p53
CEA
CA19.9
TIMP-1
Spondin-2, DcR3, Trail-R2, Reg IV, MIC 1
PSME3
NNMT
CRMP-2
SELDI (apolipoprotein C1, C3a-desArg, alpha1-antitrypsin, transferrin)
HNP 1-3
MIF
M-CSF
M2-PK
Prolactin
Septin 9
Five-gene panel (CDA, BANK1, BCNP1, MS4A1, MGC20553)
CCSA-2, -3 -4
MMP-9, -7
Laminin
Stool
Stool
Stool
Stool
Stool
Serum 
Serum 
Serum 
Serum 
Serum 
Serum 
Serum 
Serum 
Serum 
Serum 
Serum 
Serum 
Serum 
Plasma 
WBC
Serum 
Serum 
Serum 
Protein
DNA
DNA
DNA
DNA
Protein
Carbohydrate
Protein
Protein
Protein
Protein
Protein
Protein
Protein
Protein
Protein
Protein
Protein
DNA
DNA
Protein
Protein
Protein
IU
CV
CV
CV
CV
IU
IU
CV
PD
PD
PD
PD
PD
PD
PD
PD
PD
PD
PD
PD
PD
PD
PD
IU, in use; CV, clinical validation; PD, preclinical development
Table 1. Noninvasive molecular biomarkers for the detection of CRC
Identification of genes or proteins that are characteristic of the 
development of cancer can potentially uncover biomarkers 
that will aid in the diagnosis of CRCs. This review will focus 
on potential biomarkers that have recently been discovered 
and may be used in the future to detect CRC using non-
invasively-collected samples as well as biomarkers that are 
currently being used in clinical settings (Table 1). 
Fecal markers
Fecal hemoglobin
Stool-based screening for CRC is simple, inexpensive and the 
least invasive method of screening available (13). FOBT, 
which is the most widely used screening modality for CRC, de-
tects hemoglobin enzymatically or immunologically (14). 
Enzymatic FOBT measures the peroxidase-like activity of he-
moglobin that originates from any source; therefore, it is sus-
ceptible to both colorectal and upper gastrointestinal bleeding. 
In addition, the ingestion of certain foods (red meats, fruits and 
vegetables) and medicines (non-steroidal anti-inflammatory 
drugs) can also yield false-positive results. Immunological 
FOBT uses antibodies that specifically detect human hemoglo-
bin; therefore, it is not impacted by plant peroxidase in the 
diet. An important limitation of the FOBT is its relatively poor 
sensitivity at detecting early-stage lesions. In addition, FOBT 
shows low sensitivity for the detection of both adenomas 
(~10%) and CRCs (40-85%). Finally, large randomized clin-
ical trials have shown that FOBT is not very reliable and that 
they reduce cancer mortality by only 30% (3, 15).
Genes and epigenetic markers
Colonocytes, which are shed into the fecal stream, provide in-
formative material that can be used to detect genes and epi-
genetic markers in feces (16). Unlike fecal blood, which is 
shed only intermittently, it is believed that colonocytes are 
shed continuously. Furthermore, the shedding of colonocytes 
from CRC occurs more frequently than from normal colonic 
epithelium. Fecal colonocytes are assessed by analyzing DNA 
mutations for targets such as K-ras, p53, and adenomatous pol-
yposis coli (APC), by analyzing epigenetic markers such as mi-
crosatellite instability (MSI), or by measuring unfragmented 
long-form DNA (L-DNA). 
    K-ras, which encodes a Ras family protein, functions as a 
guanine nucleotide binding protein that is involved in a signal 
transduction pathway that includes the phosphatidylinosi-
tol-3-kinase and serine/threonine protein kinase B pathways 
(17). K-ras mutations have been found in 40-50% of sporadic 
colon cancers and adenomas (18). In addition, studies have 
demonstrated that K-ras mutations are present in aberrant crypt 
foci (a suspected pre-cancerous lesion) in 13-95% of all CRC 
cases (19-21), which suggests that K-ras mutations may be an 
important early event in tumorogenesis. 
    p53 encodes a tumor suppressor protein that regulates the ex-
pression of genes involved in apoptosis, angiogenesis, the cell 
cycle and maintenance of the genome (22). Approximately 50% 
of all human cancers contain mutated p53 genes, and 30-60% of 
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CRCs have demonstrated mutations in the gene that vary based 
on the stage, grade and location of the cancer (23) These muta-
tions appear to be formed relatively late in the genesis of CRC, 
and altered p53 has only a modest impact on outcome. 
Therefore, the relatively low mutation rate of p53 in early-stage 
tumors limits its sole use in DNA-based detection of CRC. 
    APC protein is another tumor suppressor that assembles on 
a scaffold protein, axin, with β-catenin and glycogen synthase 
kinase 3β to coordinate the regulation of β-catenin signaling 
(24). Inactivation of the APC protein is responsible for both in-
herited and sporadic forms of CRC. Like K-ras, mutation of 
APC appears to be an early-genetic event in the progression 
from adenoma to carcinoma, which indicates its potential for 
use as a screening marker. However, unlike K-ras, the muta-
tions are distributed throughout the coding region, thereby 
making it technically difficult and time consuming to detect all 
of the potential mutations during screening programs for CRC 
(21, 25, 26). 
    Microsatellites are stretches of short DNA sequences that 
contain a motif of 1-5 nucleotides that are tandemly repeated 
(27). The most common microsatellite in human DNA is a di-
nucleotide repeat of cytosine and adenine. These tandem re-
peats occur throughout the human genome. MSI occurs when 
microsatellites undergo a change in length that covers approx-
imately 15% of the CRC. MSI tumors show a better prognosis 
than stage-matched microsatellite stable tumors (28). In spora-
dic CRCs, the development of MSI most commonly occurs due 
to epigenetic silencing of the DNA mismatch repair gene, 
MLH1 (29). There are several MSI markers, among which 
BAT26 is probably the most widely used. 
    Shedding of colonocytes is a normal consequence of ex-
foliation (30). Untransformed colonocytes are shed con-
tinuously from the colonic mucosa. These cells usually under-
go apoptosis, which is characterized by DNA fragmentation 
and laddering. Conversely, malignant colonocytes shed from 
CRC tumors have a decreased rate of apoptosis relative to nor-
mal colonocytes, which facilitates detection of intact genomic 
DNA (L-DNA) as a potential stool-based marker. Boynton et al. 
(31) amplified six genomic fragments of different length from 
each of four different genetic loci (APC, p53, BRCA1, and 
BRCA2) using fecal specimens collected from 25 CRC patients 
and 77 controls. In their study, when a positive L-DNA was de-
fined as >18 bands detected from a possible 24 bands (4 loci 
× 6 fragments), the specificity for CRC detection was 97% and 
the sensitivity was 57%.
    A large population-based study conducted by Imperiale et 
al. revealed that a fecal DNA panel consisting of 21 mutations 
(3 in the K-ras gene, 10 in the APC gene, and 8 in the p53 
gene; the MSI marker BAT-26; and L-DNA) detects a greater 
proportion of important colorectal neoplasia than FOBT with-
out compromising specificity (32). In addition, the sensitivity 
of the fecal DNA panel was 52% for invasive caners and 41% 
for invasive cancers plus adenomas with high-grade dysplasia, 
whereas that of the FOBT was 13% for the former and 14% for 
the latter. In subjects with negative findings on colonoscopy, 
the DNA panel had a specificity of 94%, whereas FOBT had a 
specificity of 95%. Taken together, the results of this study 
clearly demonstrate that the DNA panel has a higher sensi-
tivity than FOBT without reduced specificity. 
Serum or blood markers
CEA
Carcinoembryonic antigen (CEA) is a high molecular weight 
glycoprotein that belongs to the immunoglobulin superfamily. 
The carboxy-terminal of CEA contains a hydrophobic region 
that is modified to provide a glycosyl phosphatidylinositol link 
to the cell membrane. Although its presence can be de-
termined in biopsy samples, it is usually identified in serum. 
This protein has been used for many years as a biomarker of 
CRCs as well as for other cancers (33). Specifically, high CEA 
levels are associated with cancer progression, and levels of the 
marker are expected to fall following cancer surgery (34). 
However, in the absence of cancer, high CEA levels may also 
occur in response to other conditions such as hepatitis, in-
flammatory bowel disease, pancreatitis, and obstructive pul-
monary disease. Furthermore, CEA may not be detected when 
cancer is in advanced stages. As a result, CEA does not pro-
vide sufficient sensitivity and reliability for the early detection 
of cancer. Indeed, using a cut-off point of 2.5 ng/ml results in 
the sensitivity of CEA for early CRC (i.e., Dukes’ A and B dis-
ease) being only 30-40% with a specificity of 87% (9). 
Therefore, the NIH does not recommend that CEA be used to 
screen for early CRC (33). Instead, the potential value of the 
CEA test lies in its use to measure the course of the progression 
of cancer as a prognostic marker once it has been diagnosed, 
with higher CEA levels being indicative of greater disease se-
verity and a poorer prognosis.
CA 19-9
Carbohydrate antigen 19-9 (CA 19-9), which is the second 
most investigated gastrointestinal tumor marker, is known to 
be a sialylated Lewis-a antigen (35). CA 19-9 was originally de-
fined by a monoclonal antibody produced by a hybridoma 
prepared from the spleen cells of a mouse that had been im-
munized with the human colorectal carcinoma cell line, SW 
1116. Although CA 19-9 is the best marker available for pan-
creatic adenocarcinoma, it is less sensitive than CEA for CRC 
and provides less information than CEA when used for mon-
itoring patients that have already been diagnosed with CRC 
(36). Other carbohydrate antigens such as CA 50, CA 195, CA 
242, CA M26, CA M25, CA M43 and CA 72-4 have also been 
evaluated extensively (37); however, due to their observed 
sensitivity, stage dependency and specificity, these antigens 
are not useful markers for the detection of CRC.
Tissue inhibitor of metalloproteinase type 1
Tissue inhibitor of metalloproteinase type 1 (TIMP-1) is a mul-
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tifunctional glycoprotein that inhibits most matrix metal-
loproteinases (MMPs). The total levels of TIMP-1 have been 
shown to be significantly higher in patients with both colonic 
and rectal cancers, while healthy blood donors have a low and 
very narrow range of plasma TIMP-1 levels (38, 39). More im-
portantly, TIMP-1 is capable of detecting early stage colon can-
cer with a sensitivity and specificity comparable to those ob-
tained when detecting late stage cancers. Conversely, patients 
with colon adenomas, inflammatory bowl diseases or primary 
breast cancer do not show increased plasma levels of total 
TIMP-1 (40). Preoperative TIMP-1 levels have been proposed 
as a stage-independent prognostic marker for CRC in multi-
variate statistical analyses in two separate high-powered stud-
ies (41, 42). However, the results of these studies revealed that 
elevated levels of TIMP-1 were not restricted to advanced 
stages of CRC alone; therefore, larger studies are required to 
validate the use of TIMP-1 for early diagnosis and evaluation of 
the prognosis of CRC.
Five- serum-marker panel (spondin-2, DcR3, Trail-R2, Reg IV, 
MIC 1)
diaDexus Inc. recently evaluated four serum biomarkers, spon-
din-2, tumor necrosis factor receptor superfamily member 6B 
(DcR3), TRAIL receptor 2 (TRAIL-R2) and Reg IV in 600 serum 
samples in collaboration with the Mayo Clinic (43). All four 
markers, as well as a fifth marker, macrophage inhibitory cyto-
kine 1 (MIC1), were found to be elevated in patients with CRC 
when compared to normal controls and patients with benign 
disease. In addition, this five-serum marker panel offers better 
sensitivity and specificity than CEA. Accordingly, the company 
is currently developing biomarker panels that include the 5 
markers as diagnostic modalities to improve the detection rate 
of early stage CRC.
Nicotinamide N-methyltransferase and proteasome activator 
complex subunit 3
Roche Diagnostics GmbH utilized two-dimensional gel elec-
trophoresis and mass spectrometry to analyze 16 matched 
CRC and adjacent normal tissue samples. Proteins found to be 
elevated in cancer tissue were then further validated with se-
rum samples. Elevated levels of nicotinamide N-methyl-
transferase (NNMT) and proteasome activator complex subunit 
3 (PSME3), which are not predicted to be secreted, were found 
in serum from patients with CRC (44, 45). Validation studies 
using 109 CRC samples, 317 healthy control samples, and 87 
samples from patients with benign bowel diseases revealed 
that the diagnostic accuracy of PSME3 was similar to that of 
CEA, and that NNMT was better than CEA at detecting CRC. 
However, the abundance of PSME3 is less stage-dependent 
than CEA.
Collapsin response mediator protein-2
Although direct analysis of human samples may sometimes be 
very challenging, discovering candidate biomarkers from can-
cer cell lines and subsequent validation in human samples is 
plausible (46, 47). By analyzing the secretomes of 21 cancer 
cell lines derived from 12 cancer types, Wu et al. identified 
collapsin response mediator protein-2 (CRMP-2) and evaluated 
it as a potential CRC biomarker in the serums of 201 CRC pa-
tients and 210 healthy controls (48). The use of CRMP-2 alone 
showed better sensitivity but poorer specificity than CEA. 
However, combined detection using CEA and CRMP-2 pro-
duced better sensitivity (77%) and specificity (95%) than de-
tection using either of these markers alone (43 and 61% sensi-
tivity, respectively; 87 and 65% specificity, respectively). 
Therefore, CRMP-2 may be a valuable serum marker when 
used in combination with CEA.
Six SELDI peaks corresponding to apolipoprotein C1, 
complement C3a-desArg, α1-antitrypsin and transferrin
Surface-enhanced laser desorption/ionization (SELDI) mass 
spectrometry is a technology that can produce proteomic fin-
gerprints from biological samples using a relatively high- 
throughput platform (49). In this method, samples are applied 
to proteinchip arrays coated with chromatographic surfaces 
and then analyzed by mass spectrometry. Martin et al. used 
SELDI to investigate the serum proteome of 62 CRC patients 
and 31 noncancer subjects (50). They identified four proteins 
with diagnostic potential: apolipoprotein C1, complement 
C3a-desArg (the stable form of C3a anaphylatoxin), α1-anti-
trypsin and transferrin. Artificial neural networks trained using 
only the intensities of six SELDI peaks corresponding to the 
identified proteins were able to classify the patients enrolled in 
the study with 95% sensitivity and 91% specificity, while the 
use of CEA to evaluate the same sample set showed 54% sen-
sitivity and 93% specificity. 
    Habermann et al. demonstrated that C3a-desArg is present 
at significantly higher levels in serum from patients with color-
ectal adenomas and carcinomas than in serum from healthy in-
dividuals (51). Specifically, in a blinded validation study (n = 
59), the use of C3a-desArg alone predicted the presence of col-
orectal malignancy with a sensitivity of 97% and a specificity 
of 96%. C3a-desArg and other proteins corresponding to 
SELDI peaks are common serum proteins, and changes in their 
concentrations most likely reflect epiphenomena rather than 
secretion by cancer cells.
α-Defensins
Two independent approaches using SELDI-TOF to analyze the 
protein profiles of colon cancer serum and protein profiles of 
CRC tumors demonstrated that human neutrophil peptides 
(HNP)-1, HNP-2 and HNP-3, also known as α-defensin-1, 
α-defensin-2, and α-defensin-3, are up-regulated in patients 
with CRC (52, 53). Indeed, the HNP1-3 level in the serum of 
48 CRC patients and 42 normal controls was capable of identi-
fying CRC with a sensitivity of 69% and a specificity of 100%. 
However, a larger study is required to refine and validate the 
diagnostic accuracy of these findings.
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Macrophage migration inhibitory factor
Based on an observation that the gene expression level of mac-
rophage migration inhibitory factor (MIF) is elevated in CRC 
tissues, our group has evaluated the use of the protein as a po-
tential biomarker for CRC. In an analysis of serum samples of 
129 patients with colon cancer and 53 healthy control sub-
jects, the serum MIF level was found to be significantly in-
creased in patients with CRC (54). Although the specificity of 
MIF is not as high as that of CEA (90.6% vs. 100.0%), MIF is 
more sensitive during early cancer detection (47.3% vs. 
29.5%), which suggests that MIF may be used as a diagnostic 
marker in CRC.
Macrophage-colony stimulating factor
The serum levels of both macrophage-colony stimulating fac-
tor (M-CSF) and granulocyte-colony stimulating factor are sig-
nificantly higher in CRC patients than in healthy subjects (55, 
56). In addition, serum levels of M-CSF are more associated 
with lymph node metastasis than CEA and CA 19-9, which 
suggests that serum M-CSF elevation in CRC patients might 
help predict the risk of lymph node metastasis of this tumor. 
Finally, M-CSF appears to offer additional information to that 
presented by classic prognostic factors. 
Prolactin
Prolactin, which is a hormone with multiple biological actions 
that is synthesized by the anterior pituitary gland, is elevated 
in patients with CRC. A study that evaluated 47 CRC patients 
and 51 healthy controls revealed that prolactin can predict 
CRC with a sensitivity and specificity of 77% and 98%, re-
spectively (57).
M2-pyruvate kinase
M2-pyruvate kinase is an isoform of glycolytic enzyme pyruvate 
kinase. Although the protein is a cytosolic enzyme, it is li-
berated into circulation via a mechanism that is not yet known. 
However, it has been suggested that M2-pyruvate kinase is re-
leased into circulation from dying cancer cells. Therefore, 
M2-pyruvate may be a useful marker for the detection of CRC. 
In addition, two independent studies revealed that the use of 
M2-pyruvate kinase for the detection of CRC has a sensitivity of 
48-58% and a specificity of 90-95%. Furthermore, when com-
bined with CEA, the sensitivity of M2-pyruvate increases with-
out decreasing the specificity (58, 59).
Methylated septin-9 DNA
The assessment of epigenetic events is one of the most promis-
ing means of identifying biomarker candidates for the early de-
tection of cancer. DNA methylation in which cytosines within 
the palindromic dinucleotide 5'-CpG-3' sequence are methy-
lated shapes the chromatin structure of DNA according to its 
functional state (60). The cancer genome is frequently charac-
terized by hypermethylation of specific genes. Therefore, 
Epigenomics AG has developed a blood-test for CRC that is 
based on methylation of SEPT9, NGFR and TMEEF2 (61). To 
evaluate this test, free-floating DNA was extracted from plasma 
samples of 133 CRC patients and 179 healthy controls in the 
same age range, and the methylation levels were then meas-
ured using restriction enzyme-based qPCR. The biomarker 
with the highest performance was found to be SEPT9, which 
was capable of detecting CRC with a specificity and sensitivity 
of 95% and 52%, respectively, when a cutoff of 0.011 μg/L of 
methylated SEPT9 DNA was used.
Five gene markers in whole blood
Gene expression patterns in the peripheral blood reflect 
changes that occur within the cells and tissues of the body 
(62). Han et al. extracted total RNA from the white blood cells 
of peripheral blood and identified differentially regulated 
genes using a microarray (63). Specifically, they used a panel 
comprised of five genes including B-cell scaffold protein with 
ankyrin repeats 1 (BANK1), B-cell novel protein 1 (BCNP1), 
cytidine deaminase (CDS), FERM domain containing 3 
(MGC20553), and membrane-spanning 4-domains, subfamily 
A, member 1 (MS4A1) to detect CRC and found that this test 
had a sensitivity of 88-94% and a specificity of 64-77%.
Other markers
Three proteins, colon cancer-specific antigen (CCSA)-2, 
CCSA-3 and CCSA-4, have shown promise as markers for the 
detection of CRC. Getzenberg et al. identified several nuclear 
matrix proteins from CRC cell lines and tested some of them to 
determine if they would be useful as cancer biomarkers (64). 
Using a cutoff value of 2 μg/ml for CCSA-3, both CRC and ad-
vanced adenoma were detected with 89% sensitivity and 82% 
specificity. In addition, the sensitivity and specificity was 85% 
and 91%, respectively, when CCSA-4 was used with a cutoff 
value of 0.3 μg/ml. Finally, the use of CCSA-2 at a cutoff of 
10.8 μg/ml had an overall specificity of 78% and sensitivity of 
97% when used to separate individuals with advanced ad-
enomas and CRC from normal, hyperplastic, and nonadvanced 
adenoma populations (65). Although the initial studies have 
had promising outcomes, the molecular identities of the three 
proteins have not yet been publically disclosed.
    Remodeling of the extracellular matrix is important in the 
development of cancers, and several extracellular matrix pro-
teins that can be liberated into circulation have been evaluated 
as potential biomarkers. The results of these evaluations have 
revealed that the serum levels of MMP9 and MMP7 depend on 
the presence of colorectal malignancy (66, 67). In addition, it 
has been suggested that serum laminin and MMP7 can be 
used as independent prognostic markers of CRC (67, 68).
Conclusion and perspectives
FOBT is currently the only screening modality for CRC. 
DNA-based fecal markers are promising but are not widely 
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used in clinical settings. In addition, a lack of sensitivity and 
specificity preclude the use of all existing serum markers for 
the early detection of CRC. CEA is used to monitor therapy in 
advanced CRC, and the preoperative level of CEA is used to 
provide prognostic information. However, there is insufficient 
evidence for routine use of other classic serum markers such 
as carbohydrate antigens and TIMP-1. Therefore, large-scale 
validation studies are required to evaluate the potential for the 
use of biomarkers that have recently been discovered through 
omics technology.
    Genomics, proteomics, and a combination of both of these 
methods play major roles in the discovery of biomarkers. As 
with many other methods, each approach has its advantages 
and disadvantages. However, in light of the fact that many im-
portant functions of proteins require post-translational mod-
ification or their interaction with other protein(s), proteomics 
will continue to play a dominant role in the biomarker field. 
Clinical proteomics as a principal tool for the detection of dif-
ferentially expressed proteins in samples from CRC patients 
versus healthy donors is required to significantly increase the 
repertoire of candidate biomarkers. In addition, steps should 
be taken to design adequate clinical trials and build a business 
model that can be used for the commercialization of newly 
discovered biomarkers. These efforts will hasten the translation 
of proteomic discoveries into clinical practice in the not-so-dis-
tant future.
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